Why SMART about second-line treatment when first-line treatment is being ignored?
Currie
Graeme P
GP
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000318:Adrenergic beta-Agonists / Q000009:adverse effects / Q000627:therapeutic use*; D000420:Albuterol / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy* / Q000401:mortality; D004359:Drug Therapy, Combination; D019983:Guideline Adherence; D006801:Humans; D015337:Multicenter Studies as Topic; D016032:Randomized Controlled Trials as Topic; D000068299:Salmeterol Xinafoate; D015996:Survival Rate; D014481:United States
D000305:Adrenal Cortex Hormones; D000318:Adrenergic beta-Agonists; D000068299:Salmeterol Xinafoate; D000420:Albuterol